NCT03694262

The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Medical College of Wisconsin · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.

Detailed description

The combination of the three proposed agents offers the opportunity to explore synergistic relationships between antiangiogenic and immunotherapy and antiangiogenic and PARPi. Increasing genetic instability by PARPi and double-strand breaks may lead to a proinflammatory state that would enhance the activity of immunotherapy, leading to synergistic response in a category of solid tumors that lack active therapy. It is expected that increased double-strand breaks may lead to increased expression of immunogenic antigens, increasing the effect of anti-PD-L1 therapy. Phase I data combining the PD-L1 inhibitor durvalamab with either olaparib or cediranib showed good tolerability and evidence of response.

Conditions

• Endometrial Cancer
• Uterine Carcinosarcoma

Interventions

Type	Name	Description
DRUG	Rucaparib	Rucaparib 600mg orally twice daily by continuous dosing
DRUG	Bevacizumab	15mg/kg IV on day 1 of every cycle
DRUG	Atezolizumab	1,200mg IV on day 1 of every cycle

Timeline

• Start date: 2019-07-19
• Primary completion: 2023-03-30
• Completion: 2026-03-10
• First posted: 2018-10-03
• Last updated: 2026-04-13
• Results posted: 2025-05-30

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study